Artificial Tears: A Systematic Review [PDF]
Clinical Optometry, 2023 David A Semp, Danielle Beeson, Amy L Sheppard, Debarun Dutta, James S Wolffsohn School of Optometry, College of Health and Life Sciences, Aston University, Birmingham, UKCorrespondence: James S Wolffsohn, Tel +44 121 2044140, Email j.s.w.wolffsohn@aston ...
Semp DA +4 more
doaj +8 more sources
Artificial tears potpourri: a literature review
Clinical Ophthalmology, 2014 Majid Moshirfar,1 Kasey Pierson,2,* Kamalani Hanamaikai,3,* Luis Santiago-Caban,1 Valliammai Muthappan,1 Samuel F Passi11Department of Ophthalmology, John A Moran Eye Center, University of Utah, Salt Lake City, UT, USA; 2University of Arizona College of ...
Moshirfar M +5 more
doaj +6 more sources
Phosphate concentration in artificial tears [PDF]
Graefe's Archive for Clinical and Experimental Ophthalmology, 2006 Background: Irrigating solutions and eye drops may contain phosphates as part of their buffer system. In the presence of epithelial keratopathy, a high concentration of phosphate favours corneal calcification. Knowledge of the phosphate concentration in artificial tear products helps to prevent this sight-threatening complication.
W Bernauer
exaly +7 more sources
Artificial tears: Promising treatment or silent threat to public health? [PDF]
Health Science Reports, 2023 Background and Aims Dry Eye Disease (DED) is a multifactorial chronic inflammatory condition of the corneal surface, attributed to insufficient or low‐quality production of tears, accounting for 5‐50% of the cases globally. Artificial tears are the first
Sanila Mughal, Syeda K. Sakina
doaj +2 more sources
Personalized Management of Dry Eye Disease: Beyond Artificial Tears [PDF]
Clinical Ophthalmology, 2022 Cynthia Matossian,1,2 Micaela Crowley,3 Laura Periman,4 Steven Sorkin5 1Matossian Eye Associates, Pennington, NJ, USA; 2Matossian Eye Associates, Doylestown, PA, USA; 3Lexington Eye Associates, Lexington, MA, USA; 4Periman Eye Institute, Seattle, WA, USA;
Matossian C +3 more
doaj +2 more sources
Management of Dry Eye Disease with Artificial Tears Containing Hyaluronic Acid and Trehalose: A Narrative Review [PDF]
Clinical OphthalmologyMelissa Barnett,1 Michelle K Rhee,2 Kendall E Donaldson3 1Baker Optometry or Alpine Blue, Davis, CA, USA; 2Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Bascom Palmer Eye Institute of Plantation, Plantation, FL,
Barnett M, Rhee MK, Donaldson KE
doaj +2 more sources
Safety and efficacy of rebamipide compared to artificial tears for the treatment of dry eye: a systematic review and meta-analysis [PDF]
BMC OphthalmologyBackground Rebamipide (RBM) is a novel drug that increases mucin secretion on the ocular surface. Nevertheless, the therapeutic efficacy of topical RBM for dry eye disease (DED) treatment remains inconclusive.
Ching-Wen Chiu, Ka-Wai Tam, I-Chan Lin
doaj +2 more sources
Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections [PDF]
Clinical Ophthalmology, 2022 Francisco Pastor-Pascual,1 Rafael Pastor-Pascual,1 Patricia Gálvez-Perez,1 Rosa Dolz-Marco,2 Roberto Gallego-Pinazo2 1Anterior Segment Department, Valencia, Spain; 2Posterior Segment Department, Valencia, SpainCorrespondence: Francisco Pastor-Pascual ...
Pastor-Pascual F +4 more
doaj +2 more sources
Effects of artificial tears on ocular surface symptoms and visual task performance in digital device users [PDF]
Scientific ReportsThis prospective, single-arm study investigates the effects of preservative-free artificial tears on ocular symptoms, visual task performance, and tear film stability in visual display terminal (VDT) users.
Sara Ortiz-Toquero +2 more
doaj +2 more sources
Artificial Tear Instillation-Induced Changes in Corneal Topography
BioengineeringThis study aims to compare changes of corneal topography (Galilei G4) before and after the instillation of artificial tears in patients with dry eye disease (DED).
Yunjin Lee +3 more
doaj +3 more sources